Press Releases

Press Releases

DateTitle 
Aug 07, 2019
BURLINGAME, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the 2019 Wedbush
Aug 01, 2019
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today
Jul 24, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Jun 02, 2019
  Clinical and laboratory results support a new immuno-oncology approach with CPI-006  via activation of immune cells and the inhibition of adenosine production Initial Results demonstrated dose-dependent disease control in patients with advanced, refractory disease when administered as a
May 28, 2019
BURLINGAME, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the Jefferies 2019 Global
May 16, 2019
Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT BURLINGAME, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
May 09, 2019
Announces Initiation of Enrollment in Phase 1/1b Trial of ITK inhibitor CPI-818 Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the
May 01, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Mar 07, 2019
BURLINGAME, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and
Mar 05, 2019
BURLINGAME, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will present at the Cowen and
Feb 06, 2019
BURLINGAME, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and
Jan 30, 2019
BURLINGAME, Calif. , Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present updated data from its lead
Jan 28, 2019
BURLINGAME, Calif. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S.
Jan 10, 2019
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
Jan 08, 2019
Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms  now enrolling patients at U.S. sites CPI-006 in combination with CPI-444 targets multiple points in the adenosine pathway BURLINGAME, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.